利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

41 条记录 (耗时 0.021 秒)

    Method and apparatus for reducing tissue damage after ischemic injury
    1.
    发明申请
    Method and apparatus for reducing tissue damage after ischemic injury 审中-公开
    缺血性损伤后组织损伤减少的方法和装置

    公开(公告)号：US20060002975A1

    公开(公告)日：2006-01-05

    申请号：US11213570

    申请日：2005-08-26

    申请人： Frank Litvack ,  Theodore Parker ,  John Shanley

    发明人： Frank Litvack ,  Theodore Parker ,  John Shanley

    IPC分类号： A61M31/00 ,  A61F2/00

    CPC分类号： A61L31/14 ,  A61F2/91 ,  A61F2/915 ,  A61F2/958 ,  A61F2002/91541 ,  A61F2250/0068 ,  A61K38/28 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/43

    摘要： A method and apparatus for the local delivery of therapeutic agents reduces myocardial tissue damage due to ischemia. A local delivery device is used for delivery of the therapeutic agents into a coronary artery which feeds the ischemic myocardial tissue. According to one example, an implantable medical device for delivering insulin locally to myocardial tissue includes a therapeutic dosage of insulin in a biocompatible polymer affixed to a stent. The therapeutic dosage of insulin is released from the stent at a therapeutic dosage and over an administration period effective to reduce ischemic injury of the myocardial tissue.

    摘要翻译： 用于局部递送治疗剂的方法和装置减少由缺血引起的心肌组织损伤。 局部递送装置用于将治疗剂递送到进行缺血性心肌组织的冠状动脉中。 根据一个示例，用于将胰岛素局部递送至心肌组织的可植入医疗装置包括固定在支架上的生物相容性聚合物中的治疗剂量的胰岛素。 胰岛素的治疗剂量以治疗剂量和超过有效减少心肌组织缺血性损伤的给药期从支架释放。

    Methods of delivering anti-restenotic agents from a stent
    2.
    发明申请
    Methods of delivering anti-restenotic agents from a stent 审中-公开
    从支架输送抗再狭窄剂的方法

    公开(公告)号：US20060178734A1

    公开(公告)日：2006-08-10

    申请号：US11325223

    申请日：2006-01-04

    申请人： Theodore Parker ,  John Shanley ,  Brett Trauthen ,  Frank Litvack ,  Stephen Diaz

    发明人： Theodore Parker ,  John Shanley ,  Brett Trauthen ,  Frank Litvack ,  Stephen Diaz

    IPC分类号： A61F2/06

    CPC分类号： A61L31/16 ,  A61F2/91 ,  A61F2210/0004 ,  A61F2230/0054 ,  A61F2250/0068 ,  A61L2300/416 ,  A61L2300/602

    摘要： A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled, extended, and substantially linear drug release profile. The method of substantially linear extended release increases the therapeutic effectiveness of administration of a given dosage. In one example, a method of reducing restenosis includes delivering paclitaxel from a stent to an artery at a minimum release rate of 1 percent of the total dosage of paclitaxel on the stent per day throughout an entire administration period from the time of implantation of the stent until the time that substantially all the paclitaxel is released from the stent.

    摘要翻译： 用于降低支架置入医疗干预后再狭窄水平的方法包括将需要治疗的受支配物，延长和基本上的支架的支架到血管组织的持续施用一定剂量的抗再狭窄剂如紫杉醇 线性药物释放曲线。 基本线性延长释放的方法增加给药剂量的给药的治疗有效性。 在一个实例中，减少再狭窄的方法包括将紫杉醇从支架输送到动脉，在从支架植入开始的整个施用期间，每天在支架上以最大释放速率将紫杉醇的总剂量的1％ 直到基本上所有的紫杉醇从支架释放出来。

    Methods and systems for delivering immunosuppressant and anti-inflammatory agents from a stent
    4.
    发明申请
    Methods and systems for delivering immunosuppressant and anti-inflammatory agents from a stent 审中-公开
    从支架输送免疫抑制剂和抗炎剂的方法和系统

    公开(公告)号：US20060204546A1

    公开(公告)日：2006-09-14

    申请号：US11375454

    申请日：2006-03-14

    申请人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

    发明人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

    IPC分类号： A61F2/06

    CPC分类号： A61F2/915 ,  A61F2/91 ,  A61F2002/91541 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416

    摘要： A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an immunosuppressant or anti-inflammatory agent from reservoirs in a stent to vascular tissue in need of treatment in a controlled, two phase drug release profile. It is envisioned that the vascular tissue in need of treatment is arterial tissue, specifically coronary arterial tissue. The agent or drug can be the calcineurin inhibitor Pimecrolimus. The drug can be held within reservoirs in the stent in a drug delivery matrix comprised of the drug and a bioresorbable polymeric material and optionally additives to regulate the drug release.

    摘要翻译： 用于降低支架置入医疗干预后再狭窄水平的方法包括将需要在受控的两相药物释放曲线中进行治疗的支架中的血管中的一个剂量的免疫抑制剂或抗炎药剂的剂量连续施用于血管组织 。 可以想象，需要治疗的血管组织是动脉组织，特别是冠状动脉组织。 该药物或药物可以是钙调神经磷酸酶抑制剂Pimecrolimus。 该药物可以在由药物和生物可再吸收的聚合物材料和任选的调节药物释放的添加剂的药物递送基质中的支架内的储存器中保持。

    Expandable medical device with beneficial agent matrix formed by a multi solvent system
    5.
    发明申请
    Expandable medical device with beneficial agent matrix formed by a multi solvent system 审中-公开
    具有由多溶剂体系形成的有益剂基质的可扩展医疗器械

    公开(公告)号：US20050100577A1

    公开(公告)日：2005-05-12

    申请号：US10830566

    申请日：2004-04-22

    申请人： Theodore Parker ,  John Shanley ,  Micheline Markey

    发明人： Theodore Parker ,  John Shanley ,  Micheline Markey

    IPC分类号： A61F2/00 ,  A61F2/06 ,  A61F2/90 ,  A61L31/10 ,  A61L31/14 ,  A61L31/16 ,  A61K38/28 ,  A61K9/22 ,  A61K31/445 ,  A61K31/7076

    CPC分类号： A61L31/148 ,  A61F2/91 ,  A61F2/915 ,  A61F2002/91541 ,  A61F2210/0076 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/14 ,  A61L31/146 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/43 ,  A61L2300/606 ,  A61L2300/61 ,  A61L2420/02 ,  A61L2420/08

    摘要： A multi solvent drug delivery matrix formation method is used to place layers into a reservoir in a stent in a stepwise manner to achieve extended delivery of water soluble, sensitive, or difficult to deliver drugs. The multi solvent matrix formation method allows the formation of a drug reservoir with a layered morphology in which the mixing between layers is limited to allow the different layers to perform different functions in controlling drug delivery. A stent having a drug delivery matrix includes a first beneficial agent layer affixed to the stent by depositing a first solution of a first polymer and a first solvent, and a second beneficial agent layer affixed to the first beneficial agent layer by depositing a second solution of a second polymer and a second solvent. The second solvent is selected so that the first polymer is substantially insoluble in the second solvent to prevent degradation of the first polymer during deposition of the second polymer. A therapeutic agent is provided in the first beneficial agent layer or the second beneficial agent layer to form a drug delivery matrix.

    摘要翻译： 使用多溶剂药物递送基质形成方法以逐步方式将层放置在支架中的储存器中以实现水溶性，敏感或难以递送的药物的延长递送。 多溶剂基质形成方法允许形成具有分层形态的药物储存器，其中层之间的混合被限制以允许不同的层在控制药物递送中执行不同的功能。 具有药物递送基质的支架包括通过沉积第一聚合物和第一溶剂的第一溶液而固定到支架上的第一有益剂层和通过沉积第一有益剂层的第二溶液 第二聚合物和第二溶剂。 选择第二溶剂使得第一聚合物基本上不溶于第二溶剂以防止第二聚合物沉积期间第一聚合物的降解。 在第一有益剂层或第二有益剂层中提供治疗剂以形成药物递送基质。

    Drug Delivery Stent with Extended In Vivo Drug Release
    7.
    发明申请
    Drug Delivery Stent with Extended In Vivo Drug Release 审中-公开
    药物输送支架与延长的体内药物释放

    公开(公告)号：US20070191935A1

    公开(公告)日：2007-08-16

    申请号：US11671642

    申请日：2007-02-06

    申请人： Theodore Parker ,  John Shanley ,  Frank Litvack

    发明人： Theodore Parker ,  John Shanley ,  Frank Litvack

    IPC分类号： A61F2/06

    CPC分类号： A61L31/16 ,  A61F2/91 ,  A61F2250/0068 ,  A61L2300/416 ,  A61L2300/602

    摘要： A method for reducing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled and extended drug release profile for a period of at least 60 days in vivo. The in vivo release profile is determined by in vivo animal experiments involving implanting a series of stents in animals, explanting the stents from the animals at selected time points, and extracting remaining drug from the explanted stents.

    摘要翻译： 用于降低支架置入医疗干预后再狭窄水平的方法包括从支架到需要在受控和延长的药物释放曲线中治疗的血管组织连续施用一定剂量的抗再狭窄剂（例如紫杉醇） 在体内至少60天的时间。 通过体内动物实验确定体内释放曲线，包括在动物中植入一系列支架，在选定的时间点从动物外植体支架，以及从移植的支架中提取剩余的药物。

    Drug delivery stent with extended in vivo release of anti-inflammatory
    9.
    发明申请
    Drug delivery stent with extended in vivo release of anti-inflammatory 审中-公开
    药物输送支架具有延长体内释放的抗炎作用

    公开(公告)号：US20060204547A1

    公开(公告)日：2006-09-14

    申请号：US11375595

    申请日：2006-03-14

    申请人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

    发明人： Thai Nguyen ,  John Shanley ,  Frank Litvack ,  Theodore Parker

    IPC分类号： A61K31/4745 ,  A61F2/06

    CPC分类号： A61F2/915 ,  A61F2/91 ,  A61F2002/91541 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416

    摘要： A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as Pimecrolimus, from the stent to vascular tissue in need of treatment in a controlled and extended drug release profile for a period of at least 45 days in vivo. The in vivo release profile is determined by in vivo animal experiments involving implanting a series of stents in animals, explanting the stents from the animals at selected time points, and extracting remaining drug from the explanted stents.

    摘要翻译： 用于降低支架放置医疗干预后再狭窄水平的方法包括将需要在受控和延长的药物释放曲线中进行治疗的支架到维管组织连续施用一定剂量的抗再狭窄剂如吡美莫司，从支架到血管组织 在体内至少45天的时间。 通过体内动物实验确定体内释放曲线，包括在动物中植入一系列支架，在选定的时间点从动物外植体支架，以及从移植的支架中提取剩余的药物。